[HTML][HTML] A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up …
N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - Vaccine, 2022 - Elsevier
Background Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …
[HTML][HTML] A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose …
Background Pneumococcal disease (PD) remains a major health concern with considerable
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with …
A Bili, S Dobson, J Quinones, W Phongsamart… - Vaccine, 2023 - Elsevier
Background Pneumococcal disease (PD) remains a major health concern globally. In
children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most …
children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most …
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
D Greenberg, PA Hoover, T Vesikari, C Peltier… - Vaccine, 2018 - Elsevier
Background Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated
with significant decrease in disease burden. However, disease caused by non-vaccine …
with significant decrease in disease burden. However, disease caused by non-vaccine …
A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
S Senders, NP Klein, N Tamimi… - The Pediatric …, 2024 - journals.lww.com
Background: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to
extend pneumococcal disease protection beyond 13-valent PCV (PCV13). Methods: This …
extend pneumococcal disease protection beyond 13-valent PCV (PCV13). Methods: This …
Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
P Korbal, J Wysocki, T Jackowska, M Kline… - The Pediatric …, 2024 - journals.lww.com
Background: Global pediatric immunization programs with pneumococcal conjugate
vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial …
vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial …
[HTML][HTML] Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States
S Senders, NP Klein, E Lamberth… - The Pediatric …, 2021 - journals.lww.com
Background: The development and widespread use of pneumococcal conjugate vaccines
(PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the …
(PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the …
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults
R McFetridge, A Sobanjo-ter Meulen, SD Folkerth… - Vaccine, 2015 - Elsevier
Background Pneumococcal disease remains an important health priority despite successful
implementation of pneumococcal conjugate vaccines (PCVs) in infant immunization …
implementation of pneumococcal conjugate vaccines (PCVs) in infant immunization …
Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States
T Payton, D Girgenti, RW Frenck… - The Pediatric …, 2013 - journals.lww.com
Background: The 7-valent pneumococcal conjugate vaccine (PCV7; serotypes 4, 6B, 9V, 14,
18C, 19F and 23F) has decreased invasive pneumococcal disease incidence. This study …
18C, 19F and 23F) has decreased invasive pneumococcal disease incidence. This study …
[HTML][HTML] A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal …
HL Platt, D Greenberg, B Tapiero… - The Pediatric …, 2020 - journals.lww.com
Background: Pneumococcal disease remains a public health priority worldwide. This phase
2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …
2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …